During these challenging times to contain COVID-19, please carefully read and follow the recommendations of your provincial and local health authorities with the updates that are provided several times a day. Individuals with HPP do not have an underlying immune deficiency and should not be at higher risk to acquire COVID-19, unless they have preexisting conditions such as chronic lung disease. Please check with your local health care provider with any medical questions. For those who are on enzyme replacement therapy with asfotase alfa please contact Innomar with any concerns re shipment of drug. If people need guidance re recommended procedures for COVID-19 advised for everyone to follow please let us know and we can help direct you to the proper websites.
Soft Bones Canada wishes you and your families health and happiness.
Discover answers to frequently asked questions and a collection of publications, resources and programs to learn more about research, treatments and living life well with HPP
Understanding what shapes access and policy empowers us to confidently engage in topics that impact our lives. It also provides researchers and health care professionals with patient insights that result in improved diagnostics, primary care and therapies.
Connecting patients and caregivers with each other and resources to build a stronger HPP community, effective in overcoming challenges through collaboration as they forge their way to a successful future with the aim to live well with HPP.